Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

Daniel A. Pollyea(University of Colorado Cancer Center), Jessica K. Altman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Rita Assi(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Dale L. Bixby, Amir T. Fathi(Massachusetts General Hospital), James M. Foran(WinnMed), Ivana Gojo(Sidney Kimmel Comprehensive Cancer Center), Aric C. Hall(University of Wisconsin Carbone Cancer Center), Brian A. Jonas(UC Davis Comprehensive Cancer Center), Ashwin Kishtagari(Breast Cancer Research Foundation), Jeffrey E. Lancet(Moffitt Cancer Center), Lori J. Maness(Susan Thompson Buffett Foundation), James K. Mangan(UC San Diego Health System), Gabriel N. Mannis(Cancer Institute (WIA)), Guido Marcucci(City Of Hope National Medical Center), Alice S. Mims(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kelsey Moriarty(Southwestern Medical Center), Moaath K. Mustafa Ali(Cleveland Clinic), Jadee Neff(Cancer Institute (WIA)), Reza Nejati(Fox Chase Cancer Center), Rebecca L. Olin(UCSF Helen Diller Family Comprehensive Cancer Center), Mary-Elizabeth Percival(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alexander E. Perl(University of Pennsylvania), Amanda Przespolewski(Roswell Park Comprehensive Cancer Center), Dinesh S. Rao(University of Colorado Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Rory M. Shallis(Yale Cancer Center), Paul J. Shami(University of Utah), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Richard M. Stone(Dana-Farber Brigham Cancer Center), Kendra Sweet(Moffitt Cancer Center), Swapna Thota(St. Jude Children's Research Hospital), Geoffrey L. Uy(Barnes-Jewish Hospital), Pankit Vachhani(O'Neal Comprehensive Cancer Center), Carly J. Cassara(National Comprehensive Cancer Network), Deborah A. Freedman-Cass(National Comprehensive Cancer Network), Katie Stehman(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
May 1, 2023
Cited by 175Open Access
Full Text

Abstract

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a myeloid malignancy. It is a rare malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. This discussion section focuses on the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for AML.


Related Papers